Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MasterCard Inc (MA) vs Novo Nordisk A/S (NVO) Price & Performance

MasterCard IncTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

MasterCard Inc vs Novo Nordisk A/S — how do they compare? MasterCard Inc trades at $561.13 (market cap $491.83B), while Novo Nordisk A/S trades at $46.45 (market cap $207.85B). The key difference: MasterCard Inc is far larger — about 2.4× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.

MANVO
Market Cap
$491.83B$207.85B
Volume
4,635,698
Sector
Consumer CyclicalHealth
52-Week High
$598.96$63.98
52-Week Low
$471.55$35.29
Enterprise Value
$504.86B$222.55B
Dividend Yield
0.62%3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MasterCard Inc

Mastercard (MA) trades at $559.88, down 0.58% today, with strong technical support at $559 and resistance at $566. The stock shows robust fundamentals, with Q2 2026 EPS beating expectations at $5.04 versus $4.77, and revenue growth accelerating to $32.79B in 2025. Analysts maintain a bullish consensus, with 79% buy ratings and a $660.85 price target, while institutional buying activity remains positive, as noted in recent SEC filings.

Outlook is positive due to consistent earnings beats, high profitability margins, and strategic initiatives in digital payments and AI. Risks include competition from emerging payment technologies like stablecoins, as highlighted by The Motley Fool on April 10, 2026, and elevated valuation multiples such as a P/E of 30.88, which may limit near-term upside if growth slows.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MasterCard Inc

Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.

Read more on MA

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO